GAP President John Dwyer wrote to the FDA in support of the Aducanumab drug developed by Biogen. Dear Dr. Woodcock, On behalf of the Global Alzheimer’s Platform Foundation (GAP) and millions of Alzheimer’s patients and caregivers across the nation, I urge the Food and Drug Administration (FDA) to approve aducanumab for treatment of early stage […]
GAP-Net site USF Health has received a grant from the NIH to study a computerized brain training exercise, and if it can reduce the disk of Alzheimer’s disease and other dementias. The National Institutes of Health (NIH) has awarded the University of South Florida (USF) total expected funds of $44.4 million over the next five […]
GAP-Net Site KU ADC has received over $1.3 million to research how exercise supports the brain as humans age. TOPEKA, Kan. (WIBW) – The University of Kansas Alzheimer’s Disease Center has received over $1 million to research how exercise could prevent Alzheimer’s. Senator Roger Marshall (R-Kan.) says the University of Kansas Alzheimer’s Disease Center has […]
GAP-Net site Kansas University ADC was granted $4.3 million from the NIH to elevate dementia care in Kansas communities. Dementia researchers are convinced the path to beating back the life-robbing disease goes directly through clinical trials fueled by research volunteers willing to join the battle. That’s why the experts at the University of Kansas Alzheimer’s Disease […]
GAP President John Dwyer speaks about GAP’s participation in the original Trailblazer trial, and our goals for TRAILBLAZER-ALZ 2. It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite some positive signals from […]
GAP-Net site Knight ADRC at Washington University in St. Louis received two grants to determine whether driving changes can identify people with mild and very mild cognitive impairment, and maybe even identify people in the earliest stage of Alzheimer’s disease. Every day in the U.S. in 2018, motor vehicle crashes killed more than 20 people […]
TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research […]
GAP-Net Site, The Cognitive and Research Center of New Jersey, talks about their participation in the GREEN MEMORY trial. The Alzheimer’s Drug, Oligomannate, approved in China and derived from seaweed, is now being studied in the U.S. in a Phase 3, multi-center clinical trial that is actively recruiting participants. Oligomannate, a drug made from seaweed […]
GAP President John Dwyer spoke about the Green Valley clinical trial’s success in China, which is now being tested in North America. A new drug extracted from seaweed and inspired by traditional Chinese medicine has come to the United States, where researchers hope it will provide the breakthrough in Alzheimer’s treatment that has eluded us […]
GAP Chairman, George Vradenburg, and The Women’s Alzheimer’s Movement founder, Maria Shriver, co-wrote a piece on what the Biden Administration needs to do to start fulfilling their promises made to Alzheimer’s patients and researchers. No president has entered the White House with as clear a focus on Alzheimer’s disease as Joe Biden. The commitment and […]
GAP-Net site Clarity Clinical Research issued the first treatment to volunteer Mark Cornue in the GREEN MEMORY study. Last week, Clarity Clinical Research administered the first research treatment in the world for the Green Memory study to Mark Cornue, a local Jordan resident and Alzheimer’s patient. The Green Memory study is a noninvasive Alzheimer’s disease clinical trial […]
GAP-Net site Kerwin Medical Center’s Citizen Scientist, Dominic Morello, a caregiver for his father with Alzheimer’s, wrote an Op-Ed on how this generations Alzheimer’s patients can make the disease a thing of the past. There are more than 100 potential Alzheimer’s treatments in the pipeline, but the majority of clinical trials for potential Alzheimer’s therapies are delayed due to enrollment […]
Some of our 2020 Citizen Scientist National Honorees were congratulated by their local officials on their social media pages. We have compiled the links here. Dr. Collins Lewis, Cornerstone Award National Honoree Missouri Senator Roy Blunt Missouri Senator Karla May Congress Women Amy Wagner Brentwood, Missouri Mayor David Dimmitt Representative Matt Willhite, Collaborator Award National […]
Dr. Collins Lewis, 2020 Citizen Scientist Cornerstone Award National Honoree, from GAP-Net site Knight Alzheimer Clinical Trial Unit at Washington University in St. Louis was congratulated for his participation in Alzheimer’s disease clinical trials by Missouri senator Roy Blunt. Dear Dr. Lewis, It is my pleasure to join your family, friends, and colleagues in congratulating […]
GAP Chairman George Vradenburg and Dr. Jeffrey Cummings co-wrote an opinion piece about why the FDA and Alzheimer’s disease scientists, regulators, and business leaders must work together to achieve a safe, effective drug for Alzheimer’s treatment. As the Food and Drug Administration moves closer to a decision about whether to approve a promising new Alzheimer’s […]
GAP-Net site JEM Research Institute talks about what COVID-19 trials and vaccines tell us about Alzheimer’s disease trials, and the need for volunteers. The White House hopes to vaccinate 100 million people in the first 100 days of the new administration. That would be a historic accomplishment from the virus to the vaccine in less […]
GAP-Net site, the University of California Irvine’s UCIMind is quoted about how music may play a role in preserving memory and delaying Alzheimer’s disease. IRVINE (CBSLA) — On Monday, it was revealed that legendary singer Tony Bennett has been battling Alzheimer’s disease for more than four years. On Monday, it was revealed that singer Tony Bennett, seen here […]
GAP-Net site Cleveland Clinic was awarded a grant by the NIH to evaluate if high-intensity exercise can prevent development of Alzheimer’s disease. The National Institutes of Health has awarded Cleveland Clinic a $6.7 million grant to evaluate if high-intensity exercise can prevent development of Alzheimer’s disease. The five-year study will assess the effect of home-based indoor cycling […]
Statement by GAP President John Dwyer on the results of the Phase 2 trial for Donanemab: We congratulate Eli Lilly on the results of the Donanemab clinical trial showing it significantly slowed the cognitive and functional decline of people with mild Alzheimer’s. This is a major step towards discovery of a disease modifying therapy. Alzheimer’s […]
Statement by Global Alzheimer’s Platform Foundation (GAP) President John Dwyer on today’s announcement that Biogen and Apple are partnering on an observational study to investigate the role Apple Watch and iPhone could play in screening for mild cognitive impairment (MCI): Today’s announcement by Biogen and Apple marks a significant step on the path to early […]
A clinical trial participant from #GAPNet site, JEM Research, talks with her husband about their experience in the Aducanumab trial, which is pending approval by the US Food and Drug Administration by March 2021. There are currently more than five million Americans living with Alzheimer’s disease… and despite ongoing research, there has been no new […]
GAP 2020 Citizen Scientist Collaborator Award National Honoree, Rep. Matt Willhite was named to the Florida House Alzheimer’s Disease Advisory Committee. This week, state House Speaker Chris Sprowls, R-Palm Harbor, reached across the aisle to name state Rep. Matt Willhite, D-Wellington, to the Alzheimer’s Disease Advisory Committee. The Alzheimer’s Disease Advisory Committee has 15 members and meets every quarter […]
GAP CSO, Dr. Richard Mohs, testified in front of US Senators about Alzheimer’s disease. He was quoted by RFD TV about how it affects rural America. While many of us are focused on the pandemic, chances are you know someone who is battling Alzheimer’s disease. Healthcare experts call it an epidemic in rural America. Lawmakers […]
Global Alzheimer’s Platform Foundation® Chief Science Officer Dr. Richard Mohs testifies at Senate hearing about the Alzheimer’s crisis. Watch the full hearing at United States Senate Committee on Finance. Washington, DC (December 16, 2020) – Today, the Chief Science Officer of the Global Alzheimer’s Platform Foundation® (GAP), Dr. Richard Mohs, testified before the Senate Committee on Finance, […]